Fig. 2From: Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experienceDistribution of cryocrit levels (a), rheumatoid factor activity (b) and complement component C4 levels (c) in 22 hepatitis C virus-positive patients with cryoglobulinaemia treated with direct-acting antiviral agents at baseline, at week 4, at the end of treatment (EoT) and 12 weeks after treatment. SVR12 Sustained virological response 12 weeks after therapy completionBack to article page